Wave Life Sciences Ltd. Q3 FY2026 earnings call

• WVE-007 (Obesity/siRNA): The Phase IIa monotherapy trial is enrolling patients with higher baseline adiposity (BMI 35-50) than Phase I, aligning with typical Phase II/III obesity populations. Management remains confident in achieving the regulatory threshold of >5% weight loss at one year, driven by fat loss while preserving lean muscle mass. A Phase IIa combination trial with incretins has been initiated, and a post-incretin maintenance trial is on track to start in Q4 2026.
• WVE-006 (AATD/RNA Editing): Following a productive FDA meeting, WAVE is planning a single two-year registrational trial for accelerated and full approval, eliminating the need for a separate confirmatory trial. The interim analysis at one year will be based on achieving an 'MZ-like phenotype' (restoring dynamic protein response). Restoration II enrollment is complete; 600 mg monthly data is expected in Q4.
• WVE-008 (PNPLA3 Liver Disease/RNA Editing): Advancing towards clinic entry in 2026. The program aims to correct the PNPLA3 I148M variant rather than just silencing it, addressing high unmet need in 9 million carriers. First-in-human study plans leverage pre-genotyped populations for efficient enrollment.
• Strategic & Operational Updates: GSK selected a new siRNA development candidate from WAVE’s PRISM platform, triggering a $12 million milestone payment due in Q4. Monica Vnuk joined as Chief Business Officer to expand partnering opportunities. The company emphasized its proprietary SPINA chemistry and stereochemistry advantages in drug design.

The company reported third-quarter revenue of $13.2 million, a significant increase from $7.6 million in the prior year quarter. This growth is attributed entirely to the ongoing collaboration agreement with GSK. No breakdown by product segment (absolute terms or revenue contribution %) is provided, as the firm operates primarily as an R&D-stage biotech with revenue derived solely from this single partnership.

• Financial Guidance: An incremental $12 million milestone payment from GSK is expected in Q4 2026 following their recent development candidate selection.
• Clinical Trial Timeline: WVE-007 Phase IIa monotherapy data may begin emerging later in 2026 (specifically analyzing 3-month body composition vs. 6-month weight loss). WVE-007 post-incretin maintenance trial initiation is targeted for Q4 2026. WVE-006 pivotal trial enrollment will commence after Q4 2026 dose/frequency optimization data is reviewed. WVE-008 CTA submission is on track for 2026.

• Regulatory Pathway Uncertainty: While the single-trial design for WVE-006 was accepted, the specific biomarkers required for full versus accelerated approval remain competitively sensitive and not fully disclosed. Regulatory expectations for obesity trials continue to evolve regarding body composition metrics versus simple weight loss.
• Clinical Outcome Risks: Failure to meet the 5% weight loss threshold in WVE-007 monotherapy or demonstrate sufficient durability in dosing regimens could impact future valuation and partnering potential.
• Competitive Landscape: Intense competition in obesity (GLP-1s) and rare liver/lung diseases requires continuous differentiation through superior efficacy profiles (e.g., muscle preservation, durable suppression) to gain market adoption and payer acceptance.

Q: With FDA clarity on the accelerated approval pathway for WVE-006, what are the requirements for full approval, and does it require functional outcomes? / A: Management confirmed a single two-year trial design without a separate confirmatory study. Full approval is predicated on delivering an 'MZ-like phenotype' (increasing M protein to >50%, decreasing Z, and restoring acute phase response) within that timeframe. They declined to disclose specific competitive endpoints but emphasized the efficiency of this unified approach.

Q: How does WAVE differentiate its WVE-007 mechanism from GLP-1s, and what is the strategy for combination and maintenance therapy? / A: WVE-007 targets inhibitin to drive fat loss while preserving muscle, unlike GLP-1s which cause significant muscle loss. This allows for potential combination therapies to enhance fat loss or serve as a maintenance 'off-ramp' to prevent weight regain after stopping incretins. A maintenance trial starts in Q4 to address the high discontinuation rates of current GLP-1 therapies.

Q: What is the status of the GSK collaboration, and how has the relationship evolved? / A: GSK recently selected a new siRNA development candidate from WAVE’s PRISM platform, validating the SPINA design and triggering a $12M Q4 milestone. CEO Paul Bolno stated the relationship is mutually beneficial, allowing GSK access to platform capabilities while WAVE retains ownership of key assets like WVE-006. The partnership continues to evolve positively despite past asset returns.

Q: What can investors expect from the upcoming 600 mg WVE-006 data in Q4, and how will it influence the pivotal trial design? / A: The 600 mg multiple-dose data will inform the optimal dose and frequency (e.g., monthly vs. bi-weekly) for the pivotal trial. Management noted that lower doses already show substantial knockdown, so the 600 mg data is primarily for modeling total exposure and duration to optimize the regimen for the registrational study.

Q: Are there any concerns about the assay used for WVE-006 biomarkers, and is it standardized across the industry? / A: Chris Wright noted extensive dialogue with the FDA regarding the LC-MS assay. The agency was comfortable with WAVE using their well-characterized assay throughout the development program. This consistency avoids redefining non-native proteins and allows for cross-comparison of data, though standardization across competitors is not yet mandated.